Associate Professor Nick Pavlakis

Medical Oncologist, Associate Professor
Medicine, Northern Clinical School

E25 - Royal North Shore Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9926 5020
E:

On this page

Themes | Keywords | Publications

 

Keywords

Cancer

Publications

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2014

   
  • Khasraw, M., Ameratunga, M., Grant, R., Wheeler, H., Pavlakis, N. (2014), Antiangiogenic therapy for high-grade glioma. The Cochrane Database of Systematic Reviews. 3(5), CD008218. [Abstract]
  • Houang, M., Sioson, L., Clarkson, A., Watson, N., Farzin, M., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Mead, S., Chou, A., Gill, A. (2014), EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology. 46(6), 501-508. [Abstract]
  • Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014), The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer. 111(6), 1122-1131. [Abstract]
  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014), Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology. 21(6), 1937-1947. [Abstract]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Mallesara, G., Gurney, H., Clark, S., Swarbrick, A., Daly, R., Horvath, L. (2014), Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer. 110(10), 2462-2471. [Abstract]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014), Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research. 2(5), 469-479. [Abstract]
  • Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Byrne, K., Dettrick, A., Leong, T., Rathi, V., Spagnolo, D., Hemmings, C., Singh, M., Moffat, D., Tsao, M., Wilner, K., Buller, R., Pitman Lowenthal, S., Arifeen, S., Binko, J., Alam, M. (2014), National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology. 10(Suppl 2), 11-17. [Abstract]
  • Karapetis, C., Jonker, D., Daneshmand, M., Hanson, J., O'Callaghan, C., Marginean, C., Zalcberg, J., Simes, J., Moore, M., Tebbutt, N., Price, T., Shapiro, J., Pavlakis, N., Gibbs, P., Van Hazel, G., Lee, U., Haq, R., Virk, S., Tu, D., Lorimer, I. (2014), PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research. 20(3), 744-753. [Abstract]
  • Paik, J., Toon, C., Benn, D., High, H., Hasovitz, C., Pavlakis, N., Clifton-Bligh, R., Gill, A. (2014), Renal Carcinoma Associated With Succinate Dehydrogenase B Mutation: A New and Unique Subtype of Renal Carcinoma. Journal of Clinical Oncology. 32(6), e10-e13. [Abstract]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014), Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports. 4, 6152. [Abstract]

2013

   
  • Cummins, M., Pavlakis, N. (2013), The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Therapeutic Advances in Medical Oncology. 5(5), 286-300. [Abstract]
  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Boyer, M., Stockler, M. (2013), A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 81(3), 422-427. [Abstract]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013), Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer. 21(3), 697-705. [Abstract]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013), Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data From Patients Seeking Compensation From the New South Wales Dust Diseases Board. Clinical Lung Cancer. 14(1), 70-77. [Abstract]
  • Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., Shapiro, J. (2013), Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy. 13(5), 597-611. [Abstract]
  • Buikhuisen, W., Burgers, J., Vincent, A., Korse, C., van Klaveren, R., Schramel, F., Pavlakis, N., Nowak, A., Custers, F., Schouwink, J., Gans, S., Groen, H., Strankinga, W., Baas, P. (2013), Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology. 14(6), 543-551. [Abstract]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., Van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Blondal, J., Lee, U., Meharchand, J., Burkes, R., Rubin, S., Simes, J., Zalcberg, J., Moore, M., Zhu, L., Jonker, D. (2013), Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology. 24(4), 953-960. [Abstract]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., Van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013), Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer. 108(4), 771-774. [Abstract]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013), Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Critical Reviews in Oncology/Hematology. 85(2), 121-135. [Abstract]
  • Hasovits, C., Pavlakis, N. (2013), EGFR-Targeted therapy and resistance. Cancer Forum. 37(2), 1-5.
  • Pavlakis, N., Solomon, B. (2013), Lung cancer beyond 2013: Many different diseases. Cancer Forum. 37(2), 1-3.

2012

   
  • Biankin, A., Waddell, N., Kassahn, K., Gingras, M., Muthuswamy, L., Johns, A., Miller, D., Wilson, P., Patch, A., Wu, J., Chang, D., Cowley, M., Gardiner, B., Song, S., Harliwong, I., Idrisoglu, S., Nourse, C., Nourbakhsh, E., Manning, S., Wani, S., Gongora, M., Pajic, M., Scarlett, C., Gill, A., Pinho, A., Rooman, I., Anderson, M., Holmes, O., Leonard, C., Taylor, D., Wood, S., Xu, C., Nones, K., Lynn Fink, J., Christ, A., Bruxner, T., Cloonan, N., Kolle, G., Newell, F., Pinese, M., Scott Mead, R., Humphris, J., Kaplan, W., Jones, M., Colvin, E., Nagrial, A., Humphrey, E., Chou, A., Chin, V., Chantrill, L., Mawson, A., Samra, J., Kench, J., Lovell, J., Daly, R., Merrett, N., Toon, C., Epari, K., Nguyen, N., Barbour, A., Zeps, N., Brancato, M., Rowe, S., Simpson, S., Martyn-Smith, M., Thomas, M., Pettit, J., Tao, J., Dipietro, R., Watson, C., Wong, R., Giry-Laterriere, M., Musgrove, E., Sutherland, R., Grimmond, S., Pearson, J., Pavlakis, N., Guminski, A., Asghari, R., Pavey, D., Das, A., Cosman, P., Ismail, K., O'Connor, C., Lam, V., McLeod, D., Pleass, H., Richardson, A., James, V., Cooper, C., Joseph, D., Sandroussi, C., Crawford, M., Gallagher, J., Texler, M., Forrest, C., Laycock, A., Epari, K., Ballal, M., Fletcher, D., Mukhedkar, S., Spry, N., Deboer, B., Chai, M., Beilin, M., Feeney, K., Ruszkiewicz, A., Worthley, C., Tan, C., Debrencini, T., Chen, J., Brooke-Smith, M., Papangelis, V., Tang, H., Barbour, A., Clouston, A., Martin, P., O'Rourke, T., Chiang, A., Fawcett, J., Slater, K., Yeung, S., Hatzifotis, M., Hodgkinson, P., Christophi, C., Nikfarjam, M., Mountain Victorian Cancer Biobank, A., Eshleman, J., Hruban, R., Maitra, A., Iacobuzio-Donahue, C., Schulick, R., Wolfgang, C., Morgan, R., Hodgin, M., Scarpa, A., Lawlor, R., Capelli, P., Beghelli, S., Corbo, V., Scardoni, M., Pederzoli, P., Tortora, G., Bassi, C., Tempero, M., Kakkar, N., Zhao, F., Qing Wu, Y., Wang, M., Muzny, D., Fisher, W., Charles Brunicardi, F., Hodges, S., Reid, J., Drummond, J., Chang, K., Han, Y., Lewis, L., Dinh, H., Buhay, C., Beck, T., Timms, L., Sam, M., Begley, K., Brown, A., Pai, D., Panchal, A., Buchner, N., De Borja, R., Denroche, R., Yung, C., Serra, S., Onetto, N., Mukhopadhyay, D., Tsao, M., Shaw, P., Petersen, G., Gallinger, S., Mann, K., Jenkins, N., Perez-Mancera, P., Adams, D., Largaespada, D., Wessels, L., Rust, A., Stein, L., Tuveson, D., Copeland, N., Hudson, T., Wheeler, D., McPherson, J., Gibbs, R. (2012), Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 491(7424), 399-405. [Abstract]
  • Michael, M., Pavlakis, N., Clingan, P., De Boer, R., Johnston, M., Clarke, S. (2012), A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology Reports. 28(3), 763-767. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012), Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Supportive Care in Cancer. 20(6), 1235-1242. [Abstract]
  • Boyer, M., Horwood, K., Pavlakis, N., DE Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012), Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology. 8(3), 248-254. [Abstract]
  • Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., Salemi, R., Scott, A., Mariadason, J., Tebbutt, N. (2012), Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology. 30(13), 1505-1512. [Abstract]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012), Management of advanced gastric cancer. Expert Review of Gastroenterology & Hepatology. 6(2), 199-208. [Abstract]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 75(2), 248-254. [Abstract]
  • Bester, L., Meteling, B., Pocock, N., Pavlakis, N., Chua, T., Saxena, A., Morris, D. (2012), Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. Journal of Vascular and Interventional Radiology. 23(1), 96-105. [Abstract]
  • Wong, M., Stockler, M., Pavlakis, N. (2012), Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2, CD003474. [Abstract]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2012), Resistance to EGFR targeted antibodies- expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer. 12, 627.

2011

   
  • Standfield, L., Weston, A., Barraclough, H., van Kooten, M., Pavlakis, N. (2011), Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology (Carlton, Vic.). 16(8), 1210-20. [Abstract]
  • Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., Whittom, R., Langer, C., O'Callaghan, C. (2011), Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22, 118-26. [Abstract]
  • Paech, D., Weston, A., Pavlakis, N., Gill, A., Rajan, N., Barraclough, H., Fitzgerald, B., Van Kooten, M. (2011), A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(1), 55-63. [Abstract]

2010

   
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010), High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research. 16(23), 5805-5813. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010), The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific journal of clinical oncology. 6(4), 342-349. [Abstract]
  • Evans, K., Richardson, M., Pavlakis, N., Morris, D., Liauw, W., Bester, L. (2010), Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres. Journal of vascular and interventional radiology : JVIR. 21(10), 1521-6. [Abstract]
  • Crinò, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., Stroiakovski, D., Thatcher, N., Tsai, C., Wu, Y., Zhou, C. (2010), Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. The Lancet Oncology. 11(8), 733-740. [Abstract]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010), Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal. 40(6), 453-458. [Abstract]
  • Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., de Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., Marx, G. (2010), Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology. 21(6), 1302-1307. [Abstract]
  • Stewart, T., Pavlakis, N., Ward, M. (2010), Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Internal medicine journal. 40(4), 303-307. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010), Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology. 21(3), 608-614. [Abstract]
  • Price, T., Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010), Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer. 9(1), 8-14. [Abstract]
  • Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010), Anti-angiogenic therapy for high grade glioma (Protocol). Cochrane Database of Systematic Reviews. 2, CD008218.
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010), Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. Journal of the Society for Integrative Oncology. 8(2), 56-64. [Abstract]

2009

   
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., Sutherland, R., Henshall, S., Horvath, L. (2009), Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research. 69(19), 7696-7703. [Abstract]
  • Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009), Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology. 43(9), 838-847. [Abstract]
  • van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009), Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25), 4089-95. [Abstract]
  • Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., Charpentier, D., Wyld, D., Jefford, M., Knight, G., Magoski, N., Brundage, M., Jonker, D. (2009), Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology. 27(11), 1822-1828. [Abstract]
  • Krieger, L., Pavlakis, N. (2009), Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer. Does size matter?. Asia Pacific Journal of Clinical Oncology. 5(2), 73-75.
  • Khasraw, M., Atkinson, C., Van Der Saag, D., Pavlakis, N., Guminski, A. (2009), Cardiac toxicity from sunitinib: Do we need to be more vigilant?. Asia-Pacific Journal of Clinical Oncology. , 217-218.
  • Stordal, B., Pavlakis, N., Davey, R. (2009), A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. (pp.225-230).United States: Humana Press.

2008

   
  • Herbertson, R., Karapetis, C., Price, T., Tebbutt, N., Pavlakis, N. (2008), Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews. 2, CD007047.
  • Krieger, L., Pavlakis, N. (2008), Evolution of biological therapies in non-small cell lung cancer. Cancer Forum. 32, 147-150.
  • Nowak, A., Feigen, M., Pavlakis, N. (2008), Clinical trials in mesothelioma: Australasia?. In: Mesothelioma from Bench Side to Clinic. (pp.0).United States: Nova Science Publishers.
  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008), The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus. 21(5), 389-394. [Abstract]